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ARTICLE
Calreticulin and integrin alpha dissociation induces
anti-inﬂammatory programming in animal models
of inﬂammatory bowel disease
Masayoshi Ohkuro1,2,3, Jun-Dal Kim1,4, Yoshikazu Kuboi3, Yuki Hayashi4, Hayase Mizukami4,
Hiroko Kobayashi-Kuramochi3, Kenzo Muramoto3, Manabu Shirato3, Fumiko Michikawa-Tanaka3, Jun Moriya3,
Teruya Kozaki3, Kazuma Takase3, Kenichi Chiba3, Kishan Lal Agarwala3, Takayuki Kimura3, Makoto Kotake3,
Tetsuya Kawahara3, Naoki Yoneda3, Shinsuke Hirota3, Hiroshi Azuma3, Nobuko Ozasa-Komura3,
Yoshiaki Ohashi3, Masafumi Muratani 5,6, Keiji Kimura1,4,7, Ieharu Hishinuma3 & Akiyoshi Fukamizu1,4
Inﬂammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a
chronic intestinal inﬂammatory condition initiated by integrins-mediated leukocyte adhesion
to the activated colonic microvascular endothelium. Calreticulin (CRT), a calcium-binding
chaperone, is known as a partner in the activation of integrin α subunits (ITGAs). The
relationship between their interaction and the pathogenesis of IBD is largely unknown. Here
we show that a small molecule, orally active ER-464195-01, inhibits the CRT binding to
ITGAs, which suppresses the adhesiveness of both T cells and neutrophils. Transcriptome
analysis on colon samples from dextran sodium sulfate-induced colitis mice reveals that the
increased expression of pro-inﬂammatory genes is downregulated by ER-464195-01. Its
prophylactic and therapeutic administration to IBD mouse models ameliorates the severity of
their diseases. We propose that leukocytes inﬁltration via the binding of CRT to ITGAs is
necessary for the onset and development of the colitis and the inhibition of this interaction
may be a novel therapeutic strategy for the treatment of IBD.
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Inﬂammatory bowel disease (IBD) is characterized by chronicrecurrent mucosal inﬂammation of the gastrointestinal tract.The recruitment of leukocytes to areas of inﬂammation is a
crucial process for the pathogenesis of IBD1,2. It is well known
that the activated integrin α subunits (ITGAs) expressed on the
surface of multiple leukocyte types become the key mediators of
adhesion and migration via interaction with adhesion molecules
such as vascular cell adhesion molecule-1 (VCAM-1) and inter-
cellular adhesion molecule-1 (ICAM-1) on the vascular endo-
thelium3. Treatment of IBD patients using monoclonal antibodies
raised against the cell surface integrin α 4 (ITGA4) has been
shown to be effective4,5.
In contrast to the cell surface portion, in the intracellular C-
terminal region of ITGAs6, there is a highly conserved amino-
acid sequence, KxGFFKR, to which calreticulin (CRT) as a
potential integrin regulator binds, resulting in enhanced leukocyte
cell adhesion7–9. Importantly, using the in situ proximity ligation
assay (PLA)10, we have veriﬁed that the interaction of CRT and
ITGA4 was speciﬁcally observed in leukocytes of the inﬂamed
colonic mucosa and non-inﬂamed site from the section of patient
with ulcerative colitis (UC) (Fig. 1a, b and Supplementary Fig. 1).
Here, to clarify whether the inhibition of CRT binding to the
cytosolic tail of ITGAs would be effective in anti-inﬂammatory
therapy for IBD patients, we attempted to ﬁnd a potent chemical
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compound to inhibit this interaction and functions of leukocyte
on the inﬂammatory conditions in vitro or in vivo, and to assess
whether the treatment with compounds exerts protection in
mouse models of IBD.
Results
Suppression of CRT binding to ITGAs by ER-464195-01. Using
a cell-free binding assay-based high-throughput screening
method (Supplementary Fig. 2), we identiﬁed the small molecule
ER-464195-01 (Fig. 1c) as a potential candidate to inhibit the
CRT–ITGAs interaction. As shown in Fig. 1d and Supplementary
Table 1, the half-maximal inhibitory concentration (IC50) of ER-
464195-01 was 0.17, 0.36, and 0.23 μM in the interaction between
CRT and the three types of ITGA peptide (α4; KAGFFKR, αL;
KVGFFKR and αM/α2/α5; KLGFFKR)8, respectively, in which the
ﬁrst ITGA4 had the lowest IC50 value. However, these interac-
tions were not inhibited by a structurally related derivative ER-
435813-01 even at concentrations of over 10 μM. The
CRT–ITGA4 interaction was also conﬁrmed in surface plasmon
resonance analysis performed using intracellular domain of
ITGA4 peptide: its dissociation constant of KD was 2.5 × 10−7
(Supplementary Fig. 3). Next, to better understand the inhibitory
mechanism of our compounds on the CRT–ITGAs interaction,
we performed 1H-15N-heteronuclear single quantum coherence
(HSQC) NMR analysis with 15N-labeled ITGA4 peptides. The
two-dimensional 15N-HSQC spectrum of ITGA4 peptide showed
a different chemical shift with CRT, and returned to spectrum of
ITGA4 peptide alone after the pre-treatment with a water-soluble
derivative of ER-464195-01, ER-339093-13 (Fig. 1e, Supplemen-
tary Figs. 4 and 5). Sequentially, we also acquired a 1D 1H NMR
spectrum of ER-339093-13 in the presence of CRT. Interestingly,
notable line broadening of the ER-339093-13 signal was observed
upon the addition of CRT, which had no effect on the signal
generated by ER-435813-01 (Fig. 1f), indicating ER-339093-13
associates with CRT.
As an alternative approach for evaluating the inhibitory effects
of our compounds for the interaction of CRT with the full-length
ITGA, we used the recombinant glutathione S-transferase (GST)-
fused CRT protein to pull-down proteins from lysates of the
human leukemic T lymphoblast Jurkat cells. The binding of
GST–CRT protein to ITGA4 was inhibited by ER-464195-01 in a
dose-dependent manner, but not by ER-435813-01 (Fig. 1g). We
then used the in situ PLA to investigate whether ER-464195-01
suppresses ITGA4-CRT interaction in activated Jurkat cells. As
shown in Fig. 1h, i, PLA signals of their interaction were induced
by the phorbol 12-myristate 13-acetate, and were signiﬁcantly
decreased by treatment with 5 μM of ER-464195-01, but not by
the same amount of ER-435813-01. Taken together, these data
indicated that ER-464195-01 directly binds to CRT, resulting in
the blockage of CRT–ITGA4 interaction.
Inhibitory effects of ER-464195-01 on the leukocyte activity.
During the inﬂammatory response, the extravasation of leuko-
cytes has been characterized by a series of steps known as
adhesion, inﬁltration and migration, which are initiated by the
activation of ITGAs with the stimulation of extra- or intracellular
factors3,11. To demonstrate the effects of ER-464195-01 on
functions of activated leukocytes, we performed the cell adhesion
assay in vitro. Divalent cations, such as Ca2+ and Mn2+, bind to
the extracellular domain of ITGAs, and also induce the ITGA-
mediated cell adhesion activity12. Interestingly, after exogenous
activation with MnCl2, the adhesion of T cells to VCAM-1 and
neutrophils to ICAM-1 was not inhibited by ER-464195-01
(Fig. 2a,b). By contrast, treating cells with ER-464195-01 dose-
dependently inhibited the phorbol 12‐ myristate 13‐acetate
(PMA)-induced T cells and the formyl-Methionyl-Leucyl-
Phenylalanine (fMLP)-stimulated neutrophils bound to VCAM-
1 (IC50= 0.15 μM) and ICAM-1 (IC50= 0.19 μM), respectively
(Fig. 2c, d). Previous studies suggested that CRT is not only
localized in the endoplasmic reticulum, but also found on the cell
surface13, where it is associated with the α2-macroglobulin
receptor CD91, as a ligand14. As shown in Fig. 2e, f and Sup-
plementary Fig. 6, through the ﬂow cytometric analysis of Jurkat
cells, we found that the cell surface levels of CRT were sig-
niﬁcantly reduced by ER-464195-01 alone, but not by ER-435813-
01 in the presence of PMA. Our ﬁndings revealed that ER-
464195-01 targets CRT for the suppressive effects on leukocyte
adhesion.
Using the delayed-type hypersensitivity response of oxazolone
(OXA)-treated mice15, we assessed the efﬁcacy of ER-464195-01
in inhibiting the inﬁltration of inﬂammatory cells into the colon.
Four hours after rectal injection of OXA, the inﬁltrated lymph
cells and glycogen-induced peritoneal exudate cells (PECs) were
induced, and were signiﬁcantly reduced by pre-treatment with
oral administration of ER-464195-01 (per os (p.o.), bolus) in a
dose-dependent manner (Fig. 2g, h). Taken together, these data
supported that ER-464195-01 prevents the adhesion and inﬁltra-
tion of leukocytes into the inﬂammatory site, which may trigger
the inhibition of the onset of IBD.
Protective effects of ER-464195-01 on DSS-induced colitis.
Next, to examine the protective effects of ER-464195-01 on the
onset of IBD, we used the DSS-induced colitis as a model for
IBD15. In 2% dextran sodium sulfate (DSS)-induced colitis mice,
the body weight, disease activity index (DAI) (Supplementary
Table 2), and colon length were signiﬁcantly attenuated by the
prophylactic administration of ER-464195-01 at the dose of 10
mg/kg (Fig. 3a–c), suggesting that the onset of IBD can be pre-
vented by ER-464195-01. It has recently been reported that
treatment with DSS in mice elevated the intestinal expression of
multiple inﬂammation-related genes16, the induction patterns of
Fig. 1 ER-464195-01 inhibits interaction of CRT with ITGA. a In situ PLA assay for the interaction of CRT with ITGA4 at the mucosa (upper) and the
vascular lumen (bottom) in the UC colon. Representative images; non-inﬂamed control (left) and the inﬂamed site (right). Right two panels of each site
(control or inﬂamed); enlarged boxes of left two panels in each site. Scale bars, 20 μm. b Quantitative analysis of a. Results are given as the mean ± SEM of
n= 3; *P < 0.05 (two-tailed t test), the inﬂamed (Inf) group versus non-inﬂamed control (Con) group. c Chemical structures of small molecules, ER-
464195-01, ER-435813-01 and ER-339093-13. d IC50 values for inhibition of CRT binding to three types of ITGA peptides. Results are given as the mean ±
SEM of n= 3 independent experiments performed in duplicate. e Expansion of two-dimensional 15N-HSQC spectra of the uniformly 15N-labeled
intracellular domain of ITGA4 (black), with the CRT (red), and with combination of CRT and ER-339093-13 (green). An overall view of the spectra is shown
in Supplementary Fig. 4. f 1H 1D NMR spectra of ER-339093-13 or ER-435813-01 with/without the CRT. Data are representative of at least two independent
experiments. g In vitro pull-down assay, a dose-dependent-speciﬁc inhibition of GST-fused CRT proteins binding to ITGA4 by ER-464195-01 or ER-435813-
01. h In situ PLA assay for CRT–ITGA4 interaction (red dots) in PMA (100 ng/mL, 30min)-stimulated Jurkat cells with 5 μM of ER-464195-01 or ER-
435813-01. Hoechst 33258 staining (blue); the nucleus. Scale bars, 20 µm. i Quantitative analysis of h, ﬁve independent experiments with at least 500 cells
scored in each experiment. Results are given as mean ± SEM of n= 5; **P < 0.01 and ***P < 0.0001 and ns (not signiﬁcant). Statistical signiﬁcance was
evaluated using one-way ANOVA with Bonferroni’s multiple comparison test
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which are highly similar to the colonic transcriptional proﬁles of
UC patients17,18.
Transcriptome of DSS-induced colitis with ER-464195-01.
Hence, to gain insight into the molecular mechanisms underlying
the prevention of DSS-induced colitis conferred by treatment of
ER-464195-01, we performed a comprehensive analysis of ER-
464195-01-mediated gene expression changes in DSS-induced
colitis using RNA sequencing (RNA-Seq). A total of 81 differ-
entially expressed genes (DEGs) (false discovery rate (FDR) P <
0.05, fold change > 2, n= 6), including only nine upregulated and
72 downregulated genes, were isolated in intestinal tissues of ER-
464195-01 alone compared with the control (normal water)
group, suggesting that there was no signiﬁcant difference between
control groups and ER-464195-01 alone (Supplementary Fig. 7
and Supplementary Data 1). We next investigated the relation-
ships among three groups (control, DSS alone, and DSS with ER-
464195-01, n= 5) by gene expression data clustering with prin-
cipal component analysis (PCA). As shown in Fig. 3d, PCA plots
showed three major distinct clusters, in which transcripts of DSS-
induced colitis with ER-464195-01 samples were clearly separated
from those of the DSS alone group. To further investigate dif-
ferentially expressed genes (FDR; P < 0.05, fold change > 2)
among the three groups, we performed pairwise comparisons of
RNA-Seq data using the CLC Genomics Workbench software19.
As shown in Supplementary Fig. 8, in comparison with the
control, 5570 (3483 up- and 2087 downregulated) unique genes
were signiﬁcantly changed in the DSS-induced colitis group.
Meanwhile, the data set of DSS-induced colitis with ER-464195-
01 groups revealed signiﬁcant changes in 1808 (837 up- and 971
downregulated) genes as compared with DSS alone. Notably, of
3483 genes upregulated by the DSS treatment, 894 transcripts
were overlapped with 971 genes downregulated by ER-464195-01
(Fig. 3e and Supplementary Data 1).
Downregulation of inﬂammation-related gene expression. To
explore whether 894 genes were involved in the inﬂammatory
response of IBD, we then conducted gene ontology (GO)
enrichment analysis using the ToppGene Suite20. As shown in
Fig. 3f, for these genes the molecular function terms revealed the
activity of cytokines and chemokines, their receptor binding, the
structural constituent of muscle and growth factor activity.
Moreover, GO biological processes were mainly enriched for the
inﬂammation-related terms. Notably, the result obtained using
the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analysis revealed a highly signiﬁcant association of inﬂammatory
diseases such as cytokine–cytokine receptor interaction, TNF
signal pathway, Jak-STAT signaling pathway, rheumatoid
arthritis and IBD. Furthermore, we also found signiﬁcant differ-
ences in the expression of key cytokines, chemokines, receptors,
inﬂammatory markers, adhesion factors and intracellular signal-
ing, recently associated with IBD (Fig. 3g)16,18. By the above
results of GO enrichment analysis, we conﬁrmed the fold changes
in the expression of four IBD-related genes that include tumor
necrosis factor Tnfa, interleukin Il1b, Il6, and Il17f, pro-
inﬂammatory cytokines in colitis and colon cancer21, by qRT-
PCR. As shown in Fig. 3h–k, these genes were signiﬁcantly
induced in DSS-treated colitis group, but not in those treated with
ER-464195-01. Moreover, it is known that TNF-α and IL-1β
induce activation of the IL-6-STAT3 pathway in immune
cells22,23, where the transcription levels of the plasma acute phase
protein serum amyloid A (SAA) family including Saa1, Saa2, and
Saa3 were promoted. These proteins trigger a potent inﬂamma-
tory response in a variety of tissues24. Interestingly, the DSS-
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induced phosphorylation of STAT3 was successfully inhibited by
the treatment with ER-464195-01 (Fig. 3l). As expected, con-
centrations of SAA were also suppressed by ER-464195-01 in sera
of 2% and 3% DSS-induced colitis mice (Fig. 3m and Supple-
mentary Fig. 9). During chronic inﬂammation, one of the most
serious complications of IBD is the development of colorectal
cancer25. Very interestingly, the expression of tumor-associated
genes including vascular endothelial growth factor Vegfa, Il23a,
Il23r, and matrix metalloprotease 9 (Mmp9) was almost com-
pletely suppressed by the prophylactic administration of ER-
464195-01 (Supplementary Fig. 10a–e). Therefore, our data of
transcriptome analysis suggested that ER-464195-01 has a role in
suppressing the activation of leukocytes and in regulating the
expression of inﬂammation-related genes in IBD model mice.
105
100
95
90
0 1 2 3 4 5 6 (days)
Bo
dy
 w
e
ig
ht
 (%
 ba
se
lin
e)
2% DSS water
ER-464195-01 (p.o., q.d.)
Control
DSS
DSS + ER-464195-01 (10 mg/kg)
**
**
4
3
2
1
0
D
is
ea
se
 a
ct
iv
ity
 in
de
x 
(0-
4)
2% DSS
ER-464195-01(10 mg/kg)
–
– –
+ +
+
n
=
5
n
=
5
n
=
5
–
–
+
–
+
+
n
=
5
n
=
5
n
=
5
**
12
9
6
3
0
Co
lo
n 
le
ng
th
 (c
m)
2% DSS
ER-464195-01(10 mg/kg)
150
100
50
PC
2 
(14
.2%
)
0
–50
–100
–150
–200 –100 0 100 200
PC1 (32.4%)
2% DSS Normal water
2% DSS
ER-464195-01
Ccl20
Ccr6
Madcam1
Cxcl13
Ccl3
Stat4
II21r
II12b
Vcam1
Ccr7
II21
II17a
II17f
II2ra
II22
II33
Ccl4
Ccl2
Sele
Cxcl3
Stat3
Ccr2
Icam1
Ccl11
Cxcl1
Saa3
ll6
ll1b
Cxcl2
Saa1
Saa2
Tnf
Cxcl10
Stat1
Stat2
<–1.2 –0.8 –0.4 0 0.4 0.8 >1.2
Expression (log2)
p-STAT3
(Y705)
STAT3
β-actin
Normal control 2%DSS
2%DSS
ER-464195-01
25
20
15
10
5
0
2% DSS
ER-464195-01
(10 mg/kg)
–
– –
+ +
+
–
– –
+ +
+
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 in
cr
ea
se
)
*** ***
Tnfa II1b
*** ***
*** ***
II6
25
20
15
10
5
0
–
– –
+ +
+
2% DSS
(10 mg/kg)
ER-464195-01
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 in
cr
ea
se
)
–
– –
+ +
+
2% DSS
ER-464195-01
(10 mg/kg)
15
10
5
0
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 in
cr
ea
se
)
*** ***
II17f
5000
4000
3000
2000
1000
0
–
– –
+ +
+
2% DSS
ER-464195-01
(10 mg/kg)
*Se
ru
m
 a
m
ylo
id
 A
 (μ
g/
m
l)
20
15
10
5
0
2% DSS
ER-464195-01
(10 mg/kg)
R
el
at
ive
 e
xp
re
ss
io
n
(fo
ld
 in
cr
ea
se
)
Control vs. DSS
(Up-regulated genes)
DSS vs. DSS + ER-464195-01
(Down-regulated genes)
2589 894
77
–log10 (P value)
0 20 40GO: molecular function (ID)
Cytokine activity (GO:0005125)
Receptor binding (GO:0005102)
Cytokine receptor binding (GO:0005126)
Structural constituent of muscle (GO:0008307)
Chemokine activity (GO:0008009)
Chemokine receptor binding (GO:0042379)
CXCR chemokine receptor binding (GO:0045236)
Growth factor activity (GO:0008083)
G-protein coupled receptor binding (GO:0001664)
Sulfur compound binding (GO:1901681)
GO: biological process (ID)
Defense response (GO:0006952)
Inflammatory response (GO:0006954)
Response to cytokine (GO:0034097)
Response to bacterium (GO:0009617)
Response to lipopolysaccharide (GO:0032496)
Immune response (GO:0006955)
Response to bacterium (GO:0009607)
Cellular response to cytokine stimulus (GO:0071345)
Response to other organism (GO:0051707)
Response to external biotic stimulus (GO:0043207)
KEGG pathway (ID)
Influenza A (217173)
Chemokine signaling pathway (99051)
Toll-like recceptor signaling pathway (83076)
Inflammatory bowel disease (IBD) (842771)
NOD-like receptor signaling pathway (122191)
Legionellosis (469200)
Rheumatoid arthritis (200309)
Cytokine-cytokine receptor interaction (83051)
TNF signaling pathway (812256)
Jak-STAT signaling pathway (83077)
Tnf, II1a, II1b, II4r.
II6, II17a, II17f,
II18rap, II22, Stat1,
Nod2, Foxp3
Normal water
2% DSS
2% DSS + ER-464195-01
a b c f
d
e
g
h i j k
m
l
Fig. 3 ER-464195-01 prevents colitis and downregulates the expression of inﬂammation-related genes in DSS-treated mice. a–c Preventing colitis of DSS-
treated mice in the prophylactic treatment with ER-464195-01. Body weight a, disease activity index (DAI) b, and colon length c. Results are given as the
mean ± SEM of n= 5; **P < 0.01 versus control group (two-way ANOVA followed by Bonferroni’s post test) (a), and *P < 0.05 and **P < 0.01; ER-464195-
01-treated groups versus DSS-treated group at day 6 (two-tailed t test) b, c. d–g, RNA-seq data. Full gene lists are in Supplementary Data 1. Principal
component analysis, PC1 (x-axis, 32.4%) and PC2 (y-axis, 14.2%) of total variation in DEGs d. Venn diagram identifying the intersection (894 genes,
magenta) of upregulated gene (DSS alone vs. control group, red) with downregulated genes (DSS with ER-464195-01 vs. DSS alone, blue) (FDR P < 0.05,
fold change > 2) e. Functional enrichment analysis of overlap 894 genes, the negative log10 of the P value. Top 10 enriched GO terms associated with
molecular function (green) and biological process (blue), and KEGG pathway analysis (red), list of matched genes with IBD gene sets in the box f.
Hierarchical cluster analysis of IBD-associated differentially expressed genes (DEGs) among control (normal water), DSS alone and DSS with ER-464195-
01 group. Red strip represents high relative expression and blue strip represents low relative expression g. h–k, Quantitative real-time PCR validation for the
expression of four genes, Tnfa (H), Il1b (I), Il6 (J), and Il7f (K). Results are given as the mean ± SEM of n= 5; ***P < 0.0001 vs. DSS-treated group (two-
tailed t test). lWestern blot for levels of the phosphorylated tyrosine residue of STAT3 in the colon of DSS-treated mice with/without ER-464195-01. Total
STAT3 and β-actin were used as loading controls. m Concentration of SAA in 2% DSS-induced colitis with/without the prophylactic treatment of ER-
464195-01. Results are given as the mean ± SEM of n= 7, *P < 0.05; ER-464195-01-treated groups versus DSS-treated group at day 6 (two-tailed t test)
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Therapeutic effects of ER-464195-01 on murine models of IBD.
Finally, to clarify the therapeutic potential of our compounds as a
drug for IBD, we used two kinds of mouse IBD models, CD4
+CD45RBhigh T-cell transfer colitis26 and DSS-induced colitis15. In
T-cell-transferred mice, the therapeutic treatment of ER-464195-01
(p.o., quaque die (q.d.) for 32 days) signiﬁcantly improved the body
weight loss and stool consistency at the dose of 10mg/kg (Sup-
plementary Fig. 11). Next, we evaluated the effects of ER-464195-01
on the colitis developed by DSS. After 5 days of exposure to 2%
DSS, ER-464195-01-treated mice (p.o., q.d. for 6 days) revealed a
signiﬁcant amelioration of body weight loss, colon shortening, and
the DAI score at a dose of 5mg/kg (Fig. 4a–c). Interestingly,
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Fig. 4 ER-464195-01 has therapeutic effects against colitis of DSS-treated mice. a–c Improving colitis of DSS-treated mice in the therapeutic treatment with
ER-464195-01 (n= 10). Body weight a, DAI b, and colon length c. d–f Improving colitis of DSS-treated mice in the therapeutic treatment with sulfasalazine
(SASP), prednisolone (PRED), or ER-464195-01 (n= 12). Results are given as the mean ± SEM of the number of animals; *P < 0.05, **P < 0.01 and
***P < 0.001 vs. DSS alone group (two-way ANOVA followed by Bonferroni’s post test) a, d, and *P < 0.05, **P < 0.01, and ***P < 0.001; SASP, PRED, or
ER-464195-01-treated group vs. DSS-treated group at day 11 b, c, or at day 9 e, f (two-tailed t test). g Hematoxylin and eosin staining for DSS-mediated
histological changes. Scale bars, 100 μm. h In situ PLA assay for the interaction of CRT with ITGA4 at the mucosa for DSS-mediated histological changes in
mice. Bottom panels; enlarged boxes. Scale bars, 20 μm. i Quantitative analysis of h. Results are given as mean ± SEM of n= 3; **P < 0.01 and ns (not
signiﬁcant). Statistical signiﬁcance was evaluated using one-way ANOVA with Bonferroni’s multiple comparison test
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ER-464195-01 appeared to have an equivalent or higher effect in
DSS-induced colitis than oral medications for IBD such as sulfa-
salazine at dose of 500mg/kg (Fig. 4d–f and Supplementary
Fig. 12). Moreover, after the DSS treatment, histologic features were
regenerated by ER-464195-01 in the time-dependent increase of
inﬁltration of inﬂammatory cells into the lamina propria and severe
colonic damage including the inﬁltration of mononuclear inﬂam-
matory cells, diffuse ulcers and crypt loss (Fig. 4g). To further
investigate whether the interaction of CRT and ITGA is induced at
leukocytes of the DSS-induced inﬂamed colonic mucosa, and is
inhibited by the therapeutic treatment of ER-464195-01, we
examined the levels of their interactions on the large intestine using
the PLA assay. Importantly, Fig. 4h, i showed that CRT–ITGA4
interactions were enhanced in the damaged intestine with DSS. By
contrast, PLA signals were not detected in the regenerated intestine
with ER-464195-01, indicating the inhibition of their interaction.
These data showed that ER-464195-01 improves DSS-induced
colitis via dissociation of CRT and ITGA4 in leukocytes.
Discussion
It has been reported that introduction of antibodies or antisense
oligonucleotides against CRT into Jurkat cells caused the inhibi-
tion of cell adhesion and that embryonic ﬁbroblasts isolated from
CRT-deﬁcient mice did not bind to cell adhesion molecules,
although the expression of ITGAs was unaltered7,27. CRT is
known as a ligand for the scavenger receptor CD91 and its
expression is downregulated in adenocarcinomas as compared
with normal mucosa28. On the other hand, we searched levels of
gene expression in the RNA-Seq database (GEO accession:
GSE83687) of a recent genome-wide association study29, and
conﬁrmed that levels of CRT expression were not signiﬁcantly
different between intestinal tissues of UC or CD patients and
controls. Furthermore, the intestinal CRT mRNA and its protein
expression were not signiﬁcantly changed among control, DSS
alone, or DSS with ER-464195-01 group in mice (Supplementary
Data 1 and Supplementary Fig. 14). Therefore, at least ER-
464195-01 is mainly involved in the dissociation of CRT and
ITGAs underlying the inﬂammatory process of IBD.
Over 30% of the patients with IBD including UC and CD will
require a surgical intervention during the course of their dis-
ease30, because no single ideal drug therapy is currently available.
Thus, there is a serious need for the development of new potential
therapeutic agents and treatment strategies for IBD. A recent
report suggested that defective signaling of IL-10, an anti-
inﬂammatory cytokine, in a lipopolysaccharide-induced colitis of
mice and in macrophages of IBD patients led to dysregulated
activation of the NLRP3 inﬂammasome and production of IL-
1β31. Intriguingly, despite no evidence concerning the functional
contribution of CRT to IL-10 signaling in macrophages, the
treatment of ER-464195-01 suppressed expression of Il10 and
Nlrp3 (Supplementary Fig. 10f, g and Supplementary Data 1) as
well as Il1b (Fig. 3i) in our DSS-induced model. Collectively, our
study demonstrates that CRT is a potential therapeutic target for
inﬂammatory disorders via the inhibition of binding to ITGAs by
ER-464195-01 in mouse models of IBD. Therefore, it is suggested
that the orally active compound provides a novel and promising
therapeutic approach for the treatment of IBD.
Methods
Antibodies. The following antibodies were purchased: anti-ITGA4 (EPR1355Y,
ab81280), anti-CRT (EPR3924, ab196159), anti-CD4 (3-4F4, ab24894), anti-
STAT3 (EPR361, ab109085) from Abcam; anti-CRT (F-4, sc-373863), anti-CRT
(N-19, sc-6468) from Santa Cruz Biotechnology; anti-CRT (FMC75, NBP1-97502)
from Novusbio; anti-ITGA4 (19676-1AP) from Proteintech; anti-phospho-STAT3
(Tyr705) (D3A7, #9145) from Cell Signaling Technology; anti-b-actin from (M177-
3) MBL International Corporation; anti-rabbit IgG-horseradish peroxidase (HRP)
(NA934) and anti-mouse IgG-HRP (NA931) from GE Healthcare.
Compounds. ER-464195-01 (1-propyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]
piperazine hydrochloride), ER-435813-01 (1-cyclopropylmethyl-4-phenylpiper-
azine hydrochloride), and ER-339093-13 (1-(cyclopropylmethyl)-4-[2-(3,3,5,5-
tetramethylcyclohexyl)phenyl] piperazine methanesulfonate) were synthesized
(>95% pure) at Eisai Co. Ltd. and are described in patent publication
WO2005063705.
Peptides. For the high-throughput screen (HTS) cell-free binding assay, we
obtained the N-terminally biotinylated ITGA peptides KVGFFKR, KAGFFKR, and
KLGFFKR from Operon Biotechnologies K.K. For NMR analysis, intracellular
domain of ITGA4, KAGFFKRQYKSILQEENRRDSWSYINSKSNDD, was cloned
into a pGEX-2T vector (GE healthcare) using BamHI-EcoRI as a fusion protein
tagged with GST. The 15N-labeled ITGA4 was expressed in Escherichia coli (BL21)
cultured in 15N-labeled C. H. L. medium (Chlorella Industry) containing 100 μg/
mL ampicillin. In the expression procedure, 1 mM of isopropyl-β-D-thiogalacto-
pyranoside (IPTG) and amino-acid solution for the C. H. L. medium were added
when the optical density at 600 nm (OD600) reached 0.6, and protein expression
was induced at 37 °C for 5 h. The cells were harvested, resuspended in 50 mL lysis
buffer (20 mM Tris [pH 7.4], 50 mM NaCl, 5 mM EDTA, 1 mM DTT, 0.2% Triton
X-100, and one tablet of Complete TabletTM (Roche)) per 1 L culture, and then
disrupted using Bioruptor (COSMO BIO). After centrifugation, the supernatant
was mixed with 5 mL (bed volume) Glutathione Sepharose 4B (GE healthcare) at 4
°C for 2 h, and poured into a Glass Econo Column® (Bio-Rad). The ﬂow-through
was mixed with 2 mL (bed volume) Glutathione Sepharose 4B (GE healthcare) at 4
°C for 1 h, and poured into the same Glass Econo Column® (Bio-Rad Laboratories,
Inc). After washing the resin with 100 mL buffer A (20 mM Tris [pH 7.4], 50 mM
NaCl, 5 mM EDTA, 1 mM DTT, and 0.2% Triton X-100), and then 50 mL buffer B
(50 mM Tris [pH 7.4], 150 mM NaCl, and 2.5 mM CaCl2), 250 units Thrombin
(GE healthcare) was added and incubated for 2.5 h with mixing to separate the
GST-tag. After collecting a ﬂow-through fraction containing ITGA4, 16 mL buffer
B was added to the column and the eluted fraction containing ITGA4 was collected.
The purity of each fraction was conﬁrmed to be more than 90% by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). These fractions were
merged and concentrated with Amicon Stirred Cell 50 ml MWCO 1k (Millipore) to
100 μM for NMR-use. For Biacore analysis, the N-terminally biotinylated
intracellular domain of the ITGA4 peptide, KAGFFKRQYKSILQEENRRDSW-
SYINSKSNDD (>95% pure), was obtained from Operon Biotechnologies K. K.
Animals. Balb/c and SCID mice (5- to 6-week-old) were purchased from Charles
River Laboratories and CLEA, respectively, in colitis experiments. All mice were
housed under a 12 h light–12 h dark cycle, and they had free access to commercial
chow and ﬁltered water. Animal care and experimental procedures were performed
in the animal facility accredited by the Health Science Center for Accreditation of
Laboratory Animal Care and Use of the Japan Health Sciences Foundation. All
protocols were approved by the Institutional Animal Care and Use Committee and
carried out in accordance with the Animal Experimentation Regulations of Eisai
Co., Ltd. and EA Pharma Co., Ltd.
Cell culture. Human leukemic T lymphoblast Jurkat cell line was purchased from
RIKEN Cell Bank and Dainippon Pharmaceutical Co., Ltd. Cells were tested using
a PCR Mycoplasma Detection Set (TAKARA) and were negative for mycoplasma
contamination. Cells were cultured and maintained in RPMI 1640 containing 10%
heat-inactivated fetal bovine serum (FBS, Cell Culture Technology) and 100 units/
mL of penicillin/streptomycin at 37 °C in a humidiﬁed 5% CO2 incubator.
Surface plasmon resonance (SPR) analysis. Real-time binding and kinetic
analysis were performed with Biacore T100 (GE Healthcare) molecular interaction
technology through SPR at 25°C. The N-terminally biotinylated intercellular
domain of the ITGA4 peptide (KAGFFKRQYKSILQEENRRDSWSYINSKSNDD,
>95% pure) was immobilized on a streptavidin-coated sensor chip (SA sensor
chip). For immobilization, biotinylated ITGA4 was diluted to 4 μM with HBS-P+
buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 150
mM NaCl, 0.05% surfactant P20) and injected at a ﬂow rate of 10 μL/min. For
kinetics analysis of the interaction between CRT (>90% pure) and immobilized
ITGA4 peptide, 40 μL of various concentrations of CRT in HBS-P buffer were
injected at a ﬂow rate of 20 μL/min. A ﬂow cell not containing peptide was used as
blank control. Surface regeneration was achieved via injection of HBS-P+ buffer
containing 50 mM NaOH and 500 mM NaCl for 30 s to dissociate bound proteins.
Sensorgrams were recorded in real time and analyzed after subtracting the blank
control. Data were ﬁtted into the global Langmuir 1:1 binding model using Biacore
T100 BIAevaluation 1.1.1 software package (GE Healthcare) in accordance with the
manufacturer’s instructions.
HTS cell-free binding assay. Human CRT was expressed as a maltose binding
protein fusion protein in Escherichia coli (E. coli, BL21) and was puriﬁed with an
amylose resin column (New England Biolabs). Each of the 3 biotinylated α integrin
peptides (KVGFFKR, KAGFFKR and KLGFFKR) was added to a CRT-coated 96-
well plate (Corning) and was then incubated in 10 mM phosphate buffer (PB), pH
7.4, in the presence of compound or vehicle for 1 h at room temperature. After the
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addition of HRP–streptavidin (GE Healthcare), the amounts of α integrin peptides
bound to CRT were analyzed by measuring the absorbance at 450 nm. Using above
HTS cell-free binding assay, Eisai-original HTS library, including one hundred
thousand chemical compounds, was screened, resulting in ﬁnding of seed
compound.
NMR analyses. Human CRT protein was cloned into the pET-19b vector
(Novagen) using NdeI-XhoI as a His-tag fusion protein. For the PCR reaction, we
used the following primers: 5′-GCCTGGCCCATATGGAGCCCGCCGTCTACTT
CAAGGAGC-3′ and 5′- GGCATGTACTCGAGCTACAGCTCGTCCTTGGCCT
GGC-3′. CRT was expressed in Escherichia coli (E. coli) BL21 cultured in Luria-
Bertani (LB) medium containing 100 μg/mL ampicillin. In the expression proce-
dure, 1 mM IPTG was added when the optical density at 600 nm (OD600) reached
0.6, and protein expression was induced at 37 °C for 5 h. The cells were harvested,
resuspended in 50 ml of lysis buffer (50 mM PB [pH8.0], 200 mM NaCl, 1 mM
DTT, and one tablet of Complete TabletTM (Roche)) per 1 l culture, and then
disrupted using Bioruptor (COSMO BIO). After centrifugation, the supernatant
was mixed with 3.75 ml (bed volume) Ni-NTA Agarose (Qiagen) at 4 °C for 1 h,
and poured into a Glass Econo Column® (Bio-Rad). After washing the resin with
37.5 mL buffer C (50 mM PB [pH8.0], 200 mM NaCl, 1 mM DTT, and 5 mM
imidazole), 7.5 ml of each buffer C containing 20, 50, 100, 200, 250, and 500 mM
imidazole was added into the column in a stepwise manner. CRT was normally
eluted in 100, 200, 250, and 500 mM fractions. After merging these fractions, the
sample was concentrated with Amicon Ultra MWCO 10000 (Millipore) to 2.5 ml
and loaded onto a HiLoad 26/60 Superdex 75 pg column (GE healthcare) equili-
brated with buffer D (50 mM PB [pH 8.0], 100 mM NaCl, and 1 mM DTT). The
purity of each fraction was conﬁrmed to be more than 90% by SDS-PAGE.
NMR samples were prepared in 200 μL of 20 mM PB, pH 5.5 in 3 mm NMR
tube, which contained 10% D2O to provide a ﬁeld-frequency lock. All NMR
experiments were performed on a Bruker Avance 700-MHz spectrometer,
equipped with a 5-mm inverse triple resonance cryogenic probe, at 303 K. Two-
dimensional 15N-HSQC spectra for the interaction analysis between 15N-ITGA4
and CRT/ER-339093-13 were collected with 128 scans and the complex points 128
(15N) × 1024 (1H). The carrier position and sweep widths were 117.5 and 33 ppm
for the 15N dimension, and 4.7 and 16 ppm for the 1H dimension. Sample
concentrations of the experiments were 4 μM 15N-ITGA4, 4 μM CRT, and 800 μM
ER-339093-13. 1H 1D spectra for the interaction analysis between CRT and
ER-339093-13 or ER-435813-01 were collected with 128 scans and a sweep width
of 11261 Hz. Sample concentrations of the experiments were 100 μM ER-339093-
13 or ER-435813-01 and 4 μM CRT.
Plasmid construct and puriﬁcation of GST fusion proteins. For the construction
of GST–CRT, we used CRT (GenBank accession number NM_004343) sequence to
design primer sets with EcoRI/XhoI sites (5′-CCGGAATTCGCCGCCGCATGCT
GCTATCCG-3′ and 5′-CCGCTCGAGTGCAGCTCGTCCTTGGCCTG-3′). The
cDNA of human CRT was ampliﬁed by PCR with total RNA from Jurkat cells as
templates. The PCR fragments were digested with EcoRI/XhoI and subcloned into
the pGEX6P-2 vector. Transformed E. coli BL21 (DE3) cells were incubated with
medium containing ampicillin for 3 h at room temperature, and then IPTG
(Sigma-Aldrich) was added to a ﬁnal concentration of 100 μM. After 2 h of
induction, harvested cells were sonicated in lysozyme-phosphate-buffered saline
(PBS) buffer containing 1 mM phenylmethylsulfonyl ﬂuoride (WAKO) and 1 ×
protease inhibitor cocktail (Nacalai Tesque). Extracts were incubated with 1% NP-
40 at 4 °C for 30 min, and were centrifuged at 14,000 rpm at 4 °C for 10 min.
Recombinant GST-fused CRT was puriﬁed on glutathione Sepharose 4B beads (GE
Healthcare).
GST pull-down assay and western blotting. Jurkat cells were resuspended in lysis
buffer (20 mM Tris-HCl (pH 7.4) 150 mM NaCl, 5 mM EDTA, pH 8.0, 1% Nonidet
P-40, 5% glycerol, and 1 × protease inhibitor cocktail) for 25 min on ice and then
centrifuged at 14,000 rpm at 4 °C for 10 min. Protein extracts of Jurkat cells were
incubated with GST and GST–CRT proteins bound to beads in lysis buffer at 4 °C
for 4 h, followed by four times for washing with ice-cold PBS buffer and lysis
buffer. Bound proteins mixed with 2 × Laemmli sample buffer (Bio-Rad) and
heated at 95 °C for 5 min and resolved by 10% SDS-PAGE were transferred to an
Immobilon-P membrane (Millipore). Membranes were blocked for 45 min at room
temperature with 5% skim milk in 1 × TBST (Tris-buffered saline and Tween 20)
buffer, and then were incubated with the appropriate primary and secondary
antibodies at 4 °C overnight and at room temperature for 1 h, respectively.
Membranes were incubated with horseradish peroxidase coupled secondary anti-
body and developed using Luminata Forte Western HRP substrate (Millipore).
Immunoreactive bands were detected by exposing to X-ray ﬁlm (Fujiﬁlm).
In situ PLA. To investigate the interaction of CRT–ITGA4 in the colon samples of
both UC patients and mice and further in Jurkat cells, in situ PLA was performed
using Duolink reagent kit Brightﬁeld and Red (Sigma-Aldrich), respectively. The
formalin-ﬁxed tissue section of patient with UC was purchased from The MT
Group, Inc. Jurkat cells were ﬁxed with ice-cold methanol for 5 min and then
washed using Hanks’ balanced salt solution (HBSS) (Thermo Fisher Scientiﬁc) for
5 min twice. Methanol-ﬁxed Jurkat cells were incubated with a blocking solution at
37 °C for 45 min, then washed with HBSS for 5 min twice. Cells were incubated
with the antibody diluent solution including anti-CRT (FMC75, 1:1000 dilution)
and anti-ITGA4 (EPR1355Y, 1:1000 dilution) at 4 °C overnight. In the usage of
colon samples of UC patient and mice, after the deparafﬁnization and heat-induced
antigen retrieval in citrate buffer (pH 6.0) for 15 min, the samples were incubated
with a blocking solution inducing 10% donkey serum (Abcam) and 10% Fc Block
(Miltenyi Biotec or BD Pharmingen) at 37 °C for 60 min, then washed with in situ
washing buffer (Sigma-Aldrich) for 5 min twice. The colon samples from UC
patient were incubated with a blocking solution including 10% Fc Block (Miltenyi
Biotec), anti-CRT (FMC75, 1:25 dilution), and anti-ITGA4 (EPR1355Y, 1:50
dilution) at 4 °C overnight. The colon samples from mouse were incubated with a
blocking solution including 10% mouse Fc Block (BD Pharmingen), anti-CRT (N-
19, 1:40 dilution) and anti-ITGA4 (19676-1-AP, 1:40 dilution) at 4 °C overnight.
The procedures for the administration of anti-CRT and anti-ITGA4 antibodies,
PLA probes (MINUS and PLUS), hybridization, ligation, ampliﬁcation, and
detection were performed according to the manufacturer’s protocol. The nuclei
were labeled with Hoechst 33,258 (1 μg/mL) for 5 min. Signals of PLA were
observed using a ﬂuorescence microscope (BZ-X710, KEYENCE) and a laser-
scanning confocal microscope (FluoView FV10i, Olympus). Quantitative analysis
of images was performed using Duolink Image Tool software (Sigma-Aldrich).
Isolation of mouse lymph cells and peritoneal exudate cells. Preparation of
lymph cells; Male Balb/c mice (6-week-old) were sensitized with 150 μL of 3%
OXA-ethanol solution placed onto the skin of the abdomen at day 0. At day 3, mice
were fasted and at day 4, the lymph nodes that were removed from OXA-sensitized
mice were passed through a cell strainer (BD Bioscience) to generate a single-cell
suspension that contained lymph cells. Erythrocytes were removed by hypotonic
lysis in ammonium chloride buffer (BD Bioscience). Preparation of mouse PECs; 1
mL sample of 10% glycogen (Sigma-Aldrich) in PBS solution was injected into the
peritoneal cavity of normal mice. Fourteen hours after the glycogen injection, the
inﬁltrated cells were collected from the peritoneal cavity. Erythrocytes were
removed by hypotonic lysis in ammonium chloride (BD Bioscience) buffer to
isolated PECs that contained almost neutrophils.
Cell adhesion assay. Human neutrophils and T cells were isolated from the
peripheral blood of healthy volunteers by means of sedimentation using dextran
(Nacalai Tesque) and Ficoll–Paque PLUS (GE Healthcare). Mononuclear cells were
collected from the interface between the plasma and the Ficoll layer, and T cells
were puriﬁed using a nylon ﬁber column (Wako Pure Chemical Industries).
Neutrophils were obtained after hypotonic lysis of contaminating erythrocytes by
the treatment with sterile water (within 10 s), as previously reported9. Cells were
attached to VCAM-1 or ICAM-1 (R&D SYSTEMS)-coated 96-well plate with
MnCl2 (2 mM, Sigma-Aldrich), PMA (10 nM, Sigma-Aldrich), or the fMLP (100
nM, Sigma-Aldrich) in the presence of ER-464195-01 or ER-435813-01 for 60 min
at 37 °C. After non-adherent cells were removed by washing, the number of
adherent cells was estimated by using the chromogenic substrate 4-nitrophenyl N-
acetyl-β-D-glucosaminide (Sigma-Aldrich), which is hydrolyzed by the ubiquitous
lysosomal enzyme hexosaminidase, and measuring the absorbance at 405 nm32.
Flow cytometric analysis of CRT expression on the cell surface. Jurkat cells
were stimulated with PMA (100 ng/mL) and dimethyl sulfoxide or compounds for
30 min. Cells were washed with PBS containing 0.3% FBS and ﬁxed with 3.7%
formaldehyde at 37 °C for 10 min. After washing with PBS (0.3% FBS), Alexa Fluor
647-conjugated anti-CRT monoclonal antibody and FITC-conjugated anti-CD4
monoclonal antibody were added and incubated at 4 °C for 1 h. After washing with
PBS (0.3% FBS), the cells were suspended in the same buffer with propidium iodide
(1 µg/mL). Expression of CRT and CD4 was measured on the FACSAria II (BD
Bioscience) and analyzed by Flowjo software (TreeStar Ashland, OR).
OXA-induced cell inﬁltration into the colon of mice. Male Balb/c mice (6-week-
old) were sensitized with 150 μL of 3% OXA-ethanol solution placed onto the skin
of the abdomen at day 0. At day 3, all of the mice were fasted and at day 4, isolated
lymph cells or PECs were labeled with 2.5 μM calcein-AM (Molecular Probes) for
30 min at 37 °C, suspended in PBS and intravenously injected into the mice. The
OXA was dissolved in peanut oil (Kanto Chemicals) to yield a concentration of 1%.
Peanut oil containing 1% OXA was added to an equal volume of ice-cold distilled
water and mixed to obtain a 0.5% OXA emulsion. Immediately, 100 μL of OXA
emulsion was intrarectally injected into the colon. ER-464195-01 or vehicle (0.5%
methyl cellulose solution, 10 mL/kg) was orally administered 30 min before the
rectal injection of OXA. Four hours after OXA injection, mice were killed and the
colons were removed. The number of calcein-AM-labeled cells that had inﬁltrated
into the colon was estimated by counting the cells placed under a ﬂuorescent
microscope (Multi Angle Microscopic System, KEYENCE).
DSS-induced colitis for prophylactic treatment. Male Balb/c mice (6–8-week
old) were allowed free access to distilled water (Otsuka Pharmaceutical) containing
2 or 3% DSS (molecular weight: 36,000–50,000; MP Biomedicals) for 6 or 7 days to
induce colitis. ER-464195-01 or vehicle was orally administered once per day for 6
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or 7 days. DAI and colon length were measured on the ﬁnal day of the DSS
treatment. DAI was evaluated as previously described33,34 with slight modiﬁcations
(Supplementary Table 2).
Measurement of SAA in sera. Serum levels of SAA were measured using an
enzyme-linked immunosorbent assay (ELISA) kit (Life Technologies).
CD4+CD45RBhigh T-cell transfer model of colitis in mice for therapeutic
treatment. CD4+CD45RBhigh T cells were isolated from the splenocytes of female
Balb/c mice (6-week-old). The spleens were passed through a cell strainer
(BD Bioscience) to generate a single-cell suspension that contained splenocytes.
Erythrocytes were removed by hypotonic lysis in ammonium chloride buffer
(BD Bioscience). After hemolysis, the CD4+ T cells were separated from the
splenocytes by negative selection using a CD4+ T-cell isolation kit (Miltenyi
Biotec) and passing the cells over a MACS LS column (Miltenyi Biotec). To isolate
CD4+CD45RBhigh T cells, CD4+ T cells were labeled with a phycoerythrin-
conjugated mouse anti-CD4 monoclonal antibody (eBioscience) and a FITC-
conjugated mouse anti-CD45RB monoclonal antibody (eBioscience). Two-color
cell sorting was performed using the FACSAria system (BD Bioscience). The sorted
CD4+CD45RBhigh T cells were suspended in PBS and then kept on ice until
required for use. At day 0, the CD4+CD45RBhigh T cells (5 × 105 cells) were
intraperitoneally transferred to female severe combined immunodeﬁciency (SCID)
mice (7-week-old). ER-464195-01 or vehicle was orally administered once per day
from day 23 to day 55. Stool consistency and colon wall thickness were determined
at day 55. Stool consistency was evaluated by using previously described scoring
method33,34 with slight modiﬁcations (Supplementary Fig. 11a).
DSS-induced colitis for therapeutic treatment. Female Balb/c mice (9- to 10-
week-old) were allowed free access to 2% DSS-containing distilled water from day 0
in order to induce colitis. At day 4 or 5, the 2% DSS-containing distilled water was
switched to distilled water, ER-464195-01 or vehicle was orally administered once
per day until the ﬁnal day. DAI and colon length were measured on the ﬁnal day
(day 9 or 11). Colons were removed and ﬁxed in 4% formalin and stained with
hematoxylin and eosin and images were obtained using a light microscope, and a
digital camera.
Quantitative real-time PCR analysis. Total RNA of mouse colon was extracted
using ISOGEN (Nippon Gene Co.) and was quantiﬁed by NanoDrop (NanoDrop
2000, Thermo Scientiﬁc). The ﬁrst strand complementary DNA was prepared by
reverse transcription using ReverTra Ace (Toyobo). qPCR analysis was performed
using SYBR Green PCR Master Mix and the Thermal Cycler Dice Real Time
System (Takara Bio Inc.). The following conditions were used: 1 cycle for 30 s at 95
°C, and then 40 cycles of 95 °C for 5 s, 60 °C for 30 s, and then 95 °C for 15 s and 60
°C for 30 s, ﬁnally 1 cycle for 15 s at 95 °C, and carried out for dissociation analysis.
Each gene expression was normalized with GAPDH mRNA content and the ΔΔCt
method was used for all real-time PCR analyses. All ampliﬁcations were performed
in duplicate. Primer sequences are given in Supplementary Table 3.
Colon lysate preparation and western blotting. Frozen colons were ground into
a ﬁne powder using a Multi-Beads Shocker (Yasui Kikai, Osaka, Japan). They were
homogenized in lysis buffer, and then centrifuged at 14,000 rpm at 4 °C for 10 min.
Supernatants were mixed with 2 × Laemmli sample buffer and heated at 95 °C for 5
min. Samples were resolved by 10% SDS-PAGE and were transferred to an
Immobilon-P membrane (Millipore). Membranes were blocked for 45 min at room
temperature with 5% skim milk in 1 × TBST buffer and were incubated with the
appropriate primary and secondary antibodies at 4 °C overnight or at room tem-
perature for 1 h. Finally, membranes were incubated with Luminata Forte Western
HRP substrate (Millipore), and immunoreactive bands were detected by exposing
to X-ray ﬁlm (Fujiﬁlm).
RNA preparation and sequencing. For the RNA sequencing analysis, total RNA
was extracted from colon of mice using ISOGEN II reagent (Nippon Gene)
according to the manufacturer’s instruction. In all, 500 ng of total RNA were
ribosomal RNA-depleted using NEBNext rRNA Depletion Kit (New England
Biolabs), and converted to Illumina sequencing library using NEBNext Ultra
Directional RNA Library Prep Kit (New England Biolabs). The library was vali-
dated with Bioanalyzer (Agilent Technologies) to determine size distribution and
concentration and sequenced on the NextSeq 500 (Illumina) with paired-end 36-
base read option. Reads were mapped on mm10 mouse reference genome and
quantiﬁed using CLC Genomics Workbench version 9.5.1 and 10.1.1 (QIAGEN).
RNA-seq data sets are deposited in the NCBI GEO under accession number
GSE98407 and GSE109728.
Identiﬁcation of DEGs. To estimate the expression pattern of transcripts among
2% DSS, 2% DSS with ER-464195-01 and control (normal water) sets, read counts
were normalized by calculating number of reads per kilobase per million for each
transcript in individual samples using the CLC Genomic Workbench software
version 9.5.1 or 10.1.135. Filtering characteristics of fold change −2 to 2 (FDR at P
< 0.05) were used to identify the DEGs. Then, comparison of distinct gene
expression patterns was visualized in a clustering heat map and PCA. Finally, a
Volcano plots were used to compare gene expression levels in terms of the log2 fold
change.
Functional enrichment analysis. To assign GO terms, molecular function and
biological process, and KEGG pathway analysis of DEGs among all three groups
were performed using ToppGene Suite (http://toppgene.cchmc.org)20.
Statistical analysis. Data are expressed as the means ± S.E.M. All statistical ana-
lyses were performed using the Prism5 (GraphPad Software) and statistical sig-
niﬁcance was determined at the *P < 0.05, **P < 0.01, and ***P < 0.0001 levels using
an unpaired t test for comparisons between two groups. For multiple comparisons,
we used one-way analysis of variance (ANOVA) followed by a Dunnett’s multiple
comparison test, a Benferroni’s multiple comparison test or two-way ANOVA
followed with Bonferroni’s post test.
Data availability. All data needed to evaluate the conclusions in the paper are
present in this study or upon reasonable request from the correspondent authors.
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